Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Status:	Completed
Conditions:	Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	9/20/2018
Start Date:	April 2009
End Date:	December 2013

A Phase 1 Study Of Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

The primary purpose of this study is to identify the maximum tolerated dose(s) (MTD) of
neratinib in combination with temsirolimus in subjects with solid tumors. This study will
also include a preliminary evaluation of efficacy, and assessment of pharmacokinetic (PK)
parameters of the combination.

Inclusion Criteria:

- Pathologic diagnosis of advanced or metastatic solid tumor.

- Measurable disease per Response Criteria in Solid Tumors (RECIST criteria).

- Incurable cancer, with disease progression following at least 1 conventional or
standard therapy for locally advanced or metastatic disease.

- Negative pregnancy test for women of child bearing potential.

Exclusion Criteria:

- Chronic treatment with corticosteroids.

- Primary central nervous system (CNS) tumors and active metastases.

- Presence of clinically significant or uncontrolled cardiac disease.

- Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major
symptom.

- Symptomatic or prior history of non-infectious interstitial pneumonitis.

We found this trial at

sites

Beth Israel Deaconess Medical Center

330 Brookline Ave
Boston, Massachusetts 02215

617-667-7000